Tissue Diagnostics Market– Statistics And Analysis & Forecast To 2027

Posted by Mrudula Anil Karmarkar on January 11th, 2021

The global tissue diagnostics market size is anticipated to reach USD 6.6 billion by 2027, growing at a CAGR of 5.9% during the forecast period, according to a new report by Grand View Research, Inc. Accelerating demand for automated tissue diagnostic systems due to the lack of skilled pathologists has driven the market. The advent of advanced imaging techniques, such as autofluorescence, that minimize the need for invasive diagnostics further supplement market growth.

The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.

The digitalization of tissue diagnostic techniques has resulted in the improvement of workflows and better patient care. Ongoing strategic models taken-up by key companies to enhance the efficiency of diagnostics also drives the market. For instance, in December 2020, Philips collaborated with Paige to provide clinical-grade artificial intelligence-based solutions to pathology laboratories. This enhanced the speed and accuracy of cancer diagnostics in laboratories.

Tissue diagnostic techniques, such as immunohistochemistry (IHC) or in situ hybridization, are used in companion diagnostics (CDx) to determine the quantity of a target analyte present in the sample. Introduction of CDx tests, such as the launch of the VENTANA HER2 Dual ISH CDx

The global tissue diagnostics market size was valued at USD 4.2 billion in 2020 and is expected to register a CAGR of 5.9% over the analysis period. Tissue diagnostics continues to serve as one of the gold standards for cancer diagnosis as these technologies capture the biological context of tumors. With an increasing incidence of cancer, the market for tissue diagnostics has witnessed high demand with lucrative growth opportunities in the near future.

A rise in the adoption rate of automated tissue-based diagnostic systems by the research institutes enables them to perform a faster diagnosis of tumors. For instance, in September 2020, West Clinic Cancer Center partnered with F. Hoffmann-La Roche Ltd. to improve patient care by using Roche’s BenchMark ULTRA Automated Advanced Staining System. This system is used for in situ hybridization or immunohistochemical testing to enable faster diagnosis of tumors.

Further key findings from the report suggest:

  •          IHC tests are highly adopted as these tests are specific and helpful in identifying the variations between different types of cancer, resulting in the largest revenue share
  •          A rise in the investments for the development of advanced infrastructure to digitalize images is anticipated to drive the digital pathology segment with the fastest CAGR.
  •          Moreover, an increase in the demand for automated modalities owing to a dearth of skilled pathologists further compliments this growth
  •          A large number of breast cancer cases coupled with a rise in the application of digital image processing techniques on histopathological samples for breast cancer detection contributes to the largest share of breast cancer
  •          Prostate cancer is anticipated to register lucrative growth owing to the extensive ongoing research pertaining to early diagnosis and prevention of this disease
  •          Hospitals dominated the market in terms of revenue share due to the high adoption of tissue diagnostics solutions. These solutions provide accurate results in minimal time than conventional testing procedures
  •          North America accounted for the largest revenue share owing to increasing collaborations between pharmaceutical and biotech firms to expand their product offerings
  •          The requirement of better laboratory management systems, growing demand for novel patient care facilities, and favorable regulatory framework, boost the Asia Pacific market at a lucrative pace
  •          Abbott, QIAGEN, Roche, Siemens, Danaher, Thermo Fisher, and Merck are some key participants operating in the tissue diagnostics market
  •          Key vendors are engaged in novel product developments, partnership, and acquisition models to maintain their revenue share in the market.

A rise in the focus of key players to develop advanced tissue-diagnostic based companion diagnostic tests drives revenue generation in the market for tissue diagnostics. For instance, in April 2020, Agilent received the FDA approval for its PD-L1 IHC 22C3 pharmDx assay designed to identify non-small cell lung cancer. It is a qualitative immunohistochemical assay designed in partnership with Merck.   

Anatomic pathology workflow continues to evolve from highly manual procedures to automated workflows, consequently driving the demand for novel solutions. Process standardization in pathology laboratories, incorporation of bioinformatics, and automated molecular diagnostic technologies have effectively addressed the issues pertaining to the lack of pathologists.

The paradigm shift from conventional pathology to digital pathology has allowed the clinicians to prioritize critical cases, reduce the turnaround time of tests, and enhance patient outcomes. For instance, in May 2020, Alverno Laboratories in partnership with Royal Phillips implemented Philips' IntelliSite Pathology Solution in its clinical laboratories to enhance laboratory efficiency, quality, and patient safety. This, in turn, surges the adoption rate of digital pathology solutions.

Have a Query? Ask Our Expert:

https://www.grandviewresearch.com/inquiry/606/ibb

The key participants operating in the market for tissue diagnostics include F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Siemens; Danaher;bioMérieux SA; QIAGEN; Becton, Dickinson and Company; Merck KGaA; GE Healthcare; BioGenex; Cell Signaling Technology, Inc.; Bio SB; DiaGenic ASA; and Agilent Technologies.

Grand View Research has segmented the global tissue diagnostics market on the basis of technology and product, application, end use:

Tissue Diagnostics Technology & Product Outlook (Revenue, USD Million, 2016 - 2027)

  •          Immunohistochemistry

o    Instruments

o    Slide Staining Systems

o    Tissue Microarrays

o    Tissue Processing Systems

o    Slide Scanners

o    Other products

o    Consumables

o    Antibodies

o    Reagents

o    Kits

  •          In Situ Hybridization

o    Instruments

o    Consumables

o    Software

  •          Primary & Special Staining
  •          Digital Pathology and Workflow

o    Whole Slide Imaging

o    Image Analysis Informatics

o    Information Management System Storage & Communication

  •          Anatomic Pathology

o    Instruments

o    Microtomes & Cryostat microtomes

o    Tissue processors

o    Automatic strainers

o    Other products

o    Consumables

o    Reagents & Antibodies

o    Probes & Kits

o    Others

Tissue Diagnostics Application Outlook (Revenue, USD Million, 2016 - 2027)

  •          Breast Cancer
  •          Non-small Cell Lung Cancer
  •          Prostate Cancer
  •          Gastric Cancer
  •          Other Cancers

Tissue Diagnostics End-Use Outlook (Revenue, USD Million, 2016 - 2027)

  •          Hospitals
  •          Research Laboratories
  •          Pharmaceutical Organizations
  •          Contract Research Organizations (CROs)

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com

Like it? Share it!


Mrudula Anil Karmarkar

About the Author

Mrudula Anil Karmarkar
Joined: July 2nd, 2020
Articles Posted: 1,808

More by this author